It’s estimated that 90% of retail investors lose money. We help you beat those odds with concise research, education and more. Click here to see our offerings.
- A clinical-stage biotech company focused on developing innovative cancer treatments
- Additionally, CRIS has a commercial asset (Erivedge) that was licensed to Roche (RHHBY) in a 2003 collaboration agreement between CRIS and Genetech (acquired by RHHBY)